HNP-1 vs Pidotimod
Head-to-head comparison of HNP-1 (Human Neutrophil Peptide 1 (Alpha-Defensin 1)) and Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) — benefits, dosing, side effects, research data, and where to buy.
| Property | HNP-1 | Pidotimod |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Neutrophil Peptide 1 (Alpha-Defensin 1) | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid |
| Molecular Weight | 3443 Da | 244.27 Da |
| Half-Life | Minutes to hours; protease-sensitive | 3-4 h |
| Amino Acids | 30 | 2 |
| Typical Dose | Research use only; no approved human dose | 400-800 mg/day |
| Route | Topical / Research parenteral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 610 | 200 |
| Research Status | Pre-clinical | Clinical |
HNP-1 Benefits
- ✓neutrophil-derived antimicrobial defense
- ✓broad pathogen killing
- ✓immune cell signaling
- ✓mucosal protection
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HNP-1 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HNP-1 Side Effects
- ⚠membrane toxicity at high concentrations
- ⚠short in vivo stability
- ⚠potential inflammation amplification
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Research Overview
HNP-1
HNP-1 has been studied as a key component of neutrophil-mediated host defense against bacteria, fungi, and some enveloped viruses. Literature also reports immunomodulatory effects, including impacts on chemotaxis, cytokine release, and barrier defense.
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.